The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

Investigative Reporter Katie LaGrone shares the personal stories of five Florida women all diagnosed with breast cancer and all denied coverage for care by their insurance companies.

Opposition councillors say the decision to back out is a "step in the wrong direction" and are calling on the Government and AstraZeneca to make a new deal. | ITV News Granada ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

With cancer rising in women under 40, there's concern about the causes — and the effects. PEOPLE's editor-in-chief Charlotte ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...